Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) Research & Development: €82 Mil (TTM As of Mar. 2026)


FRA:GU5 Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd FRA:GU5
68 GF Score
Price €1.55
GF Value €2.33
Valuation Significantly Undervalued
! 6 Warning Signs
View Full Analysis

What is Guangzhou Baiyunshan Pharmaceutical Holdings Co Research & Development?

Guangzhou Baiyunshan Pharmaceutical Holdings Co FRA:GU5 -1.27% 68 Research & Development is €82 Mil as of Mar. 2026. GuruFocus rates FRA:GU5 with a GF Score™ of 68/100 and a GF Value™ of €2.33 (Significantly Undervalued). The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Guangzhou Baiyunshan Pharmaceutical Holdings Co's Research & Development for the three months ended in Mar. 2026 was €20 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €82 Mil.

Guangzhou Baiyunshan Pharmaceutical Holdings Co  (FRA:GU5) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Guangzhou Baiyunshan Pharmaceutical Holdings Co Research & Development Related Terms

Guangzhou Baiyunshan Pharmaceutical Holdings Co Research & Development Historical Data

* Premium members only.

The historical data trend for Guangzhou Baiyunshan Pharmaceutical Holdings Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guangzhou Baiyunshan Pharmaceutical Holdings Co Research & Development Chart

Guangzhou Baiyunshan Pharmaceutical Holdings Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 121.54 110.96 100.45 100.18 80.22

Guangzhou Baiyunshan Pharmaceutical Holdings Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.34 17.09 18.95 26.42 19.92
FRA:GU5
68GF Score
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd FRA:GU5
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Guangzhou Baiyunshan Pharmaceutical Holdings Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €82 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €82 Mil mean?
Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) has a Research & Development of €82 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Guangzhou Baiyunshan Pharmaceutical Holdings Co and its competitors.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co's Research & Development too high?
Guangzhou Baiyunshan Pharmaceutical Holdings Co's current Research & Development is €82 Mil. Overall, Guangzhou Baiyunshan Pharmaceutical Holdings Co has a GF Score™ of 68/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Guangzhou Baiyunshan Pharmaceutical Holdings Co's Research & Development compare to MCK and COR?
Guangzhou Baiyunshan Pharmaceutical Holdings Co's Research & Development of €82 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Distribution company?
A good Research & Development depends on the Medical Distribution industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Guangzhou Baiyunshan Pharmaceutical Holdings Co and its competitors. Guangzhou Baiyunshan Pharmaceutical Holdings Co's current Research & Development is €82 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) is currently considered Significantly Undervalued. The stock's GF Value™ is €2.33, compared to a current price of €1.55 — trading 33.5% below its estimated fair value. The current Research & Development is €82 Mil. Guangzhou Baiyunshan Pharmaceutical Holdings Co's overall GF Score™ is 68/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5), the current Research & Development is €82 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) Overvalued in 2026?

Based on GuruFocus' analysis, Guangzhou Baiyunshan Pharmaceutical Holdings Co stock appears to be undervalued. The current stock price of €1.55 is trading 33.5% below its estimated GF Value™ of €2.33. GuruFocus considers Guangzhou Baiyunshan Pharmaceutical Holdings Co to be Significantly Undervalued.

Key valuation signals for FRA:GU5:

  • Research & Development: €82 Mil
  • GF Value™: €2.33 vs. price of €1.55 (33.5% below fair value)
  • GF Score™: 68/100 with 6 warning signs

No single metric tells the full story. See the FRA:GU5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Guangzhou Baiyunshan Pharmaceutical Holdings Co Business Description

Other Exchanges 00874:Hong Kong600332:China
Address 45 Sha Mian North Street, Liwan District, Guangdong Province, Guangzhou, CHN, 510130
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is engaged in the pharmaceutical and healthcare industry, focusing on the development of a full industrial chain covering research, manufacturing, and distribution. The group operates through five reportable segments. The Modern Chinese Medicine segment involves the R&D, manufacturing, and sale of proprietary Chinese and natural medicines. The Chemical Pharmaceutical Technology segment focuses on chemical drugs, APIs, and intermediates. The Natural Beverages segment produces and sells health-oriented beverage products. The Pharmaceutical Commerce segment is engaged in the wholesale, retail, and import/export of medicines and medical devices. The Other Segments include biotechnology innovation, consumer health, and medical services.
68GF Score

Get the complete analysis for FRA:GU5

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.55
Price
€2.33
GF Value